Cited 0 times in
Clinical Characteristics and Treatment Pathway of Patients Treated with Helicobacter pylori Infection-A Single Center Cohort Study Using Common Data Model
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최윤진 | - |
dc.date.accessioned | 2023-04-07T01:13:39Z | - |
dc.date.available | 2023-04-07T01:13:39Z | - |
dc.date.issued | 2022-08 | - |
dc.identifier.issn | 1738-3331 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/193827 | - |
dc.description.abstract | Background/Aims Changing trends in the Helicobacter pylori (H. pylori) eradication protocol have not been investigated after the publication of the third-revised Korean guideline in 2013. We aimed to analyze the clinical characteristics of H. pylori-infected patients alongside their treatment protocols using a common data model (CDM). Materials and Methods A 16-year electronic health record (of 1,689,604 patients from 2004 to 2019) was converted into a CDM in Kangdong Sacred Heart Hospital. We extracted records of patients who underwent the rapid urease test or serum anti-H. pylori IgG assay. The treatment protocols were visualized using a sunburst plot. We investigated the clinical characteristics and medication history of patients who underwent a urea breath test after clarithromycin-based eradication therapy. Results Out of 29,458 patients tested for H. pylori infection, 7,647 received a treatment protocol. Among them, 72.5% received a 7~14 days protocol comprising a proton pump inhibitor (PPI), amoxicillin, and clarithromycin. The proportion of patients treated with the first-line protocol (PPI, bismuth, tetracycline, and metronidazole) slightly increased from 1.9% (before 2014) to 3.3% (after 2014) (P<0.001). The percentages of patients with of previous exposure to macrolides (14.7% vs. 5.5%, P<0.001) or amoxicillin (10.6% vs. 7.3%, P=0.006) were higher in patients with previous clarithromycin-based eradication failure. Conclusions The H. pylori treatment protocol was not significantly modified despite the updates in the clinical guideline. There was only 1.4 percentage point increase in bismuth-based quadruple therapy as first-line eradication therapy even after the announcement of revised Korean guideline in 2013. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | Korean | - |
dc.publisher | 대한 Helicobacter 및 상부위장관 연구학회 | - |
dc.relation.isPartOf | Korean Journal of Helicobacter and Upper Gastrointestinal Research | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Clinical Characteristics and Treatment Pathway of Patients Treated with Helicobacter pylori Infection-A Single Center Cohort Study Using Common Data Model | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Seung In Seo | - |
dc.contributor.googleauthor | Tae Jun Kim | - |
dc.contributor.googleauthor | Yoon Jin Choi | - |
dc.contributor.googleauthor | Chang Seok Bang | - |
dc.contributor.googleauthor | Yong Kang Lee | - |
dc.contributor.googleauthor | Moon Won Lee | - |
dc.contributor.googleauthor | Su Youn Nam | - |
dc.contributor.googleauthor | Woon Geon Shin | - |
dc.identifier.doi | 10.7704/kjhugr.2022.0010 | - |
dc.contributor.localId | A05984 | - |
dc.relation.journalcode | J02030 | - |
dc.subject.keyword | Common data model | - |
dc.subject.keyword | Treatment | - |
dc.contributor.alternativeName | Choi, Yoon Jin | - |
dc.contributor.affiliatedAuthor | 최윤진 | - |
dc.citation.volume | 22 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 214 | - |
dc.citation.endPage | 221 | - |
dc.identifier.bibliographicCitation | Korean Journal of Helicobacter and Upper Gastrointestinal Research, Vol.22(3) : 214-221, 2022-08 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.